A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf.
95 Efficacy, damage accrual and predictors of response to belimumab in active sle patients: a large italian multicenter prospective study
2017
Poster Session
unpublished
Preserved Fulltext
95 Table 1 Refractory prominent clinical manifestation at baseline. Table 2 Disease features at baseline, 12 and 24 months (mean±SD). Abstract 95
doi:10.1136/lupus-2017-000215.95
fatcat:5x56jizz5ngq3hmybl67smyjoq